PTC Therapeutics, Inc. Payments to Acquire Equity Method Investments
PTC Therapeutics, Inc. (PTCT) reported Payments to Acquire Equity Method Investments of $100.00 thousand for the 12-month period ending 2021-12-31, per its 10-K filed 2024-02-29.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireEquityMethodInvestments · last filed 2024-02-29
- PTC Therapeutics, Inc. payments to acquire equity method investments for the quarter ending 2021-12-31 was $0.00.
- PTC Therapeutics, Inc. payments to acquire equity method investments for the quarter ending 2021-09-30 was $0.00.
- PTC Therapeutics, Inc. payments to acquire equity method investments for the quarter ending 2021-06-30 was $0.00.
- PTC Therapeutics, Inc. payments to acquire equity method investments for the quarter ending 2021-03-31 was $100.00K.
- PTC Therapeutics, Inc. payments to acquire equity method investments for fiscal 2021 was $100.00K.
- PTC Therapeutics, Inc. payments to acquire equity method investments for fiscal 2019 was $4.00M.
- PTC Therapeutics, Inc. payments to acquire equity method investments for fiscal 2018 was $0.00.
- PTC Therapeutics, Inc. payments to acquire equity method investments for fiscal 2017 was $0.00.
| Period end | Payments to Acquire Equity Method Investments 3 month | Payments to Acquire Equity Method Investments 6 month | Payments to Acquire Equity Method Investments 9 month | Payments to Acquire Equity Method Investments 12 month |
|---|---|---|---|---|
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $0.00 derived: sum of 2 quarters · filed 2024-02-29 | $0.00 derived: sum of 3 quarters · filed 2024-02-29 | $100.00K 10-K · filed 2024-02-29 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-27 | $0.00 derived: sum of 2 quarters · filed 2022-10-27 | $100.00K 10-Q · filed 2022-10-27 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $100.00K 10-Q · filed 2022-08-04 | ||
| 2021-03-31 | $100.00K 10-Q · filed 2022-05-03 | |||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-29 | $0.00 10-Q · filed 2020-10-29 | ||
| 2020-06-30 | $0.00 10-Q · filed 2020-08-05 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-22 | $0.00 derived: sum of 2 quarters · filed 2022-02-22 | $4.00M 10-K · filed 2022-02-22 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-29 | $4.00M 10-Q · filed 2020-10-29 | ||
| 2019-06-30 | $4.00M 10-Q · filed 2020-08-05 | |||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $0.00 derived: sum of 2 quarters · filed 2020-03-02 | $0.00 10-K · filed 2020-03-02 | |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-30 | $0.00 10-Q · filed 2019-10-30 | ||
| 2018-06-30 | $0.00 10-Q · filed 2019-08-06 | |||
| 2017-12-31 | $0.00 10-K · filed 2020-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |